Loading the section
The price of Neurocrine Biosciences, Inc. (NBIX) on October 9, 2026 is 142.44 USD, +0.84% on the day. Over 52 weeks the stock traded between 122.14 USD and 186.12 USD; the price now sits 32% of the way up that range. Over the past year the price changed by +2.42%. The P/E ratio is 21.4, which is below the sector median (24.8). Market capitalization is 14.29 billion USD, rank 7 among 128 stocks of the same industry with a known capitalization.
Closing prices for 09 October 2026
Next earnings report: 27 October 2026 · Earnings calendar
Neurocrine Biosciences, Inc. trades on Nasdaq under the ticker NBIX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks NBIX has traded between 122.14 $ and 186.12 $. As of 09 October 2026 the price stood 31.73 % of the way from the 52-week low to the high.
Over one year NBIX shares rose 2.42 %; over six months they rose 10.51 %. Volatility over 90 days is 34.10 %. Dividends are not included: this is price change only, as of 09 October 2026.
NBIX trades at a price-to-earnings ratio of 21.4, below the sector median of 24.8. Price to sales is 4.6, above the sector median of 3.9. Price to book is 4.2, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 141.33 | 143.55 | 140.02 | 142.44 | 1M |
| 08 October 2026 | 142.88 | 143.02 | 140.34 | 141.25 | 1M |
| 07 October 2026 | 145.33 | 145.88 | 143.21 | 143.47 | 1M |
| 06 October 2026 | 145.56 | 145.77 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Neurocrine treats neurological and hormonal disorders — above all involuntary movements caused by antipsychotics.
The main drug relieves involuntary movements that develop in some patients after long use of psychiatric medication. The condition is persistent, the course of treatment long, and alternatives few — hence steady recurring revenue.
The disorder is under-diagnosed: a general practitioner does not always recognise it, so growth depends on educating psychiatrists as much as on the drug itself. The second line is congenital adrenal hyperplasia, where a new medicine allows hormone doses to be reduced. Risks: the patent term, competition and insurer decisions. Development continues in psychiatry, where the pipeline is the main source of value beyond the current drug. The company pays no dividend.
Address:6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130, US
Neurocrine Biosciences, Inc. reported revenue of 3.1B $ and net income of 669M $ over the last four quarters. Net margin is 21.55 %. Revenue changed by +28.59 % year over year. Earnings per share are 6.50 $. Market capitalisation is 14.3B $.
NBIX has a return on equity of 19.62 %, above the sector median of −41.68 %. Return on assets is 13.63 %, above the sector median of −32.11 %. Operating margin is 25.43 %, above the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| 141.39 |
| 145.51 |
| 1M |
| 05 October 2026 | 142.94 | 146.92 | 142.48 | 144.21 | 2M |
| 02 October 2026 | 141.41 | 144.56 | 140.36 | 143.18 | 2M |
| 01 October 2026 | 140.94 | 143.74 | 139.61 | 140.71 | 2M |
| 30 September 2026 | 138.33 | 142.91 | 137.63 | 141.84 | 2M |
| 29 September 2026 | 138.26 | 141.07 | 136.31 | 138.35 | 1M |
| 28 September 2026 | 137.76 | 140.59 | 136.78 | 140.44 | 1M |
| 25 September 2026 | 138.94 | 138.94 | 137.02 | 138.40 | 1M |
| 24 September 2026 | 138.54 | 140.63 | 137.00 | 138.94 | 1M |
| 23 September 2026 | 141.97 | 142.25 | 139.32 | 139.49 | 2M |
| 22 September 2026 | 144.17 | 144.26 | 141.78 | 142.25 | 1M |
| 21 September 2026 | 146.15 | 146.26 | 143.45 | 143.96 | 1M |
| 18 September 2026 | 152.63 | 152.63 | 146.06 | 146.23 | 3M |
| 17 September 2026 | 151.14 | 152.07 | 149.71 | 151.83 | 1M |
| 16 September 2026 | 150.34 | 151.31 | 149.00 | 149.50 | 1M |
| 15 September 2026 | 156.70 | 156.70 | 149.15 | 150.02 | 1M |
| 14 September 2026 | 158.00 | 159.19 | 156.57 | 157.22 | 785,500 |